IL6R block CAR-T transgenic vector for alleviating CRS, preparation method thereof
AssigneeShanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd
InventorsLei Yu, Liqing Kang, Zhou Yu, Nan Xu
Life of this patent
Estimating the term…
Loading patent…
AssigneeShanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd
InventorsLei Yu, Liqing Kang, Zhou Yu, Nan Xu
Estimating the term…
An IL6R block CAR-T transgenic vector for alleviating CRS includes: AmpR sequence containing ampicillin resistance gene (SEQ ID NO: 1); prokaryotic replicon pUC Ori sequence (SEQ ID NO: 2); virus replicon SV40 Ori sequence (SEQ ID NO: 3); eWPRE enhanced posttranscriptional regulatory element of hepatitis B virus (SEQ ID NO: 11); human EF1a promoter (SEQ ID NO: 12); lentiviral packaging cis-elements for lentiviral packaging; humanized single-chain antibody fragment IL6RscFv1 (SEQ ID NO: 21), IL6RscFv2 (SEQ ID NO: 22), or IL6RscFv3 (SEQ ID NO: 23) of human IL6R; IRES ribosome binding sequence (SEQ ID NO: 25); IL6 signal peptide (SEQ ID NO: 26); human antibody Fc segment (SEQ ID NO: 27); and chimeric antigen receptors of the second or third generation CAR for integrating recognition, transmission and initiation. A preparation method of the IL6R block CAR-T transgenic vector and an application thereof in a preparation of drugs for alleviating CRS.
A CAR-T transgenic vector for alleviating cytokine release syndrome (CRS) by blocking IL6R, said vector comprising:
The CAR-T transgenic vector of 1, wherein the chimeric antigen receptors of the second-generation CAR comprises:
Dependencies are inferred from the claim text.